Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Virus or bacteriophage
Reexamination Certificate
2006-10-10
2006-10-10
Campell, Bruce R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Virus or bacteriophage
C424S093100, C435S235100, C435S236000, C435S239000
Reexamination Certificate
active
07118740
ABSTRACT:
A method for treating cancer cells is provided comprising directly or systemically administering a therapeutically effective dose of an attenuated measles virus. In one embodiment, the therapeutically effective dose is from about 103pfus to about 1012pfus and is delivered by direct injection into a group of cancer cells or via intravenous injection.
REFERENCES:
patent: 4108983 (1978-08-01), Wallack
patent: 4500512 (1985-02-01), Barme
patent: 4985244 (1991-01-01), Makino et al.
patent: 5001692 (1991-03-01), Farla et al.
patent: 5137727 (1992-08-01), Eckenhoff
patent: 5262359 (1993-11-01), Hierholzer
patent: 5304367 (1994-04-01), Biegon
patent: 5713858 (1998-02-01), Heruth et al.
patent: 5738985 (1998-04-01), Miles et al.
patent: 5980508 (1999-11-01), Cardamone et al.
patent: 6012034 (2000-01-01), Hamparian et al.
patent: 6026316 (2000-02-01), Kucharczyk et al.
patent: 6083751 (2000-07-01), Feldhaus et al.
patent: 6095976 (2000-08-01), Nachtomy et al.
patent: 6110461 (2000-08-01), Lee et al.
patent: 6896881 (2005-05-01), Russell et al.
patent: 0 700 995 (1996-03-01), None
patent: WO 97/12032 (1997-04-01), None
patent: WO 00/76450 (2000-12-01), None
Smith et al. Cancer, vol. 9 No. 6, pp. 1211-1218, Nov.-Dec. 1956.
Gura , Science 278:1041-1042, Nov. 1997.
Bateman et al. Gene Therapy 6, Suppl 1:S6, Abstract 24, Oct. 1999.
Linardakis et al. Gene Therapy 6, Suppl 1:S4, Abstract 13, Oct. 1999.
Weibel et al. Archives of Disease in Childhood 48:532-536, 1973.
Usonis et al. Pediatr Infect Dis J, 18:42-48, 1999.
Duprex et al. Journal of Virology 73/11:9568-9575, Nov. 1999.
Galanis et al. Gene Therapy 6, Suppl 1:S7, Abstract 28, Oct. 1999.
Russell et al. Proceedings of the American Association for Cancer Research 41:259, Abstract #1648, Mar. 2000.
Taqi et al. The Lancet, May 16, 1981: 112.
Okuno et al. Biken Journal 21:37-49, 1978.
Segni et al. Giornale di Malattie Infettive e Parassitarie, 44/11:839-846, 1992.
Wyde et al. Vaccine 12/8:715-722, 1994.
Chisum et al., Principles of Patent Law, Foundation Press1998, pp. 628-630.
Johnston et al., Journal of Virology, vol. 73 No. 8, pp. 6903-6915 (Aug. 1999).
Patterson et al., Virology, vol. 267 No. 1, pp. 80-89 (Feb. 2000).
Bowie et al, Science, vol. 247 No. 4948, pp. 1306-1310 (Mar 1990).
Attenuvax®, Merck & Co., Inc., West Point, PA 19466, USA, Sep. 8, 2000.
Schattner, A., Rager-Zisman, B., Bloom, B.R., (1985). Persistent Viral Infection Affects Tumorigenicity of a Neuroblastoma Cell Line, Cellular Immunology 98, 103-114.
World Health Organization, Requirements for measles, mumps and rubella vaccines and combined vaccine (live), (1994), WHO Technical Report Series, No. 840, p. 102-120.
Mitus, Anna, et al., Attenuated Measles Vaccine in Children with Acute Leukemia, (1962), American Journal of Diseases of Children, vol. 103m p. 243-246.
Kuzumaki, Noboru, Kobayashi, Hiroshi, (1978), Reduced Transplantability of Syngenic Mouse Tumors Superinvected with Membrane Viruses in NU/NU Mice, Transplantation Copyright by The Williams & Wilkins Co., vol. 22. No. 6.
Reichard, Kirk W., et al., (1992) Newcastle Disease Virus Selectively Kills Human Tumor Cells, Journal of Surgical Research 52, 448-453.
Kim, David H., (2000), Replication-Selective Microbiological agents: fighting cancer with targeted germ warfare, The Journal of Clinical Investigation, vol. 105, No. 7.
Hoegen, Paul Von, Weber, Ernst, Schirrmacher, Volker, (1988), Modification of Tumor cells by a law dose of Newcastle Disease Virus. Augmentation of the tumor-specific T cell response in the absence of an anti-viral response, Eur. J. Immunol. 18; 1159-1166.
Bateman, Andrew, et al., (2000), Fusogenic Membrane Glycoproteins As a Novel Class of Genes for the Local and Immune-mediated Control of Tumor Growth, Cancer Research 60, 1493-1497.
Schirrmacher, V., et al., (1999), Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus, Gene Therapy 6, 63-73.
Schirmacher, V., et al. (1998), Immunization With Virus-Modified Tumor Cells.
Sinkovics, Joseph G., Horvath, Joseph C., (2000), Newcastle disease virus (NDV): brief history of its oncolytic strains, Journal of Clinical Virology 14 1-15.
Albonico, H.U., Braker, H.U., Husler, J., (1998), Febrile infectious childhood diseases in the history of cancer patients and matched controls, Medical Hypotheses 51, 315-320.
Von Hoegen, Paul, Weber, Ernst, Schirrmacher, Volker (1988), Modification of tumor cells by a low does of Newcastle Disease Virus. Augmentation of the tumor-specific T cell response in the absence of an anti-viral response, Eur. J. Immunol. 18: 1159-1166.
Paillard, “Bystander Effects in Enzyme/Prodrug Gene Therapy”, (Oct. 10, 1997),Human Gene Therapy8:1733-1736.
Bluming & Ziegler, “Regression of Burkitt's Lymphoma in Association with Measles Infection”, (Jul. 10, 1971),The Lancet105-106.
Asada, “Treatment of Human Cancer with Mumps Virus”, (1974),Cancer34:1907-1928.
Robbins & Rapp, “Inhibition of Measles Virus Replication by Cyclic AMP”, (1980),Virology106: 317-326.
Robbins, “Stimulation of Measles Virus Replication by Cyclic Guanosine Monophosphate”, (1991),Intervirology32:204-208.
Reichard, et al., “Newcastle Disease Virus Selectively Kills Human Tumor Cells”, (1992),Journal of Surgical Research52:448-453.
Taqi et al., “Regression of Hodgkin's Disease After Measels”, (May 16, 1981),The Lancet1112.
GenBank Accession No. U60282, Jun. 1996.
Alemany et al., “Replicative adenoviruses for cancer therapy,”Nature Biotechnol.,2000, 18:723-727.
Andreansky et al., “The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors,”Proc. Natl. Acad. Sci. USA,1996, 93:11313-11318.
Arbit et al., “Quantitative studies of monoclonal antibody targeting to disialoganglioside GD2in human brain tumors,”Eur. J. Nucl. Med.,1995, 22:419-426.
Bae et al., “Genomic Differences between the Diabetogenic and Nondiabetogenic Variants of Encephalomyocarditis Virus,”Virology,1989, 170:282-287.
Bennett et al., “Fusion of Green Fluorescent Protein with the Zeocin™-Resistance Marker Allows Visual Screening and Drug Selection of Transfected Eukaryotic Cells,”Biotechniques,1998, 24(3):478-482.
Berg et al., “Physiological functions of endosomal proteolysis,”Biochem. J.,1995, 307:313-326.
Bolt and Pedersent, “The Role of Subtilisin-like Proprotein Convertases for Cleavage of the Measles Virus Fusion Glycoprotein in Different Cell Types,”Virology,1998, 252:387-398.
Cathomen et al. “A Matrix-less Measles Virus is Infectious and Elicits Extensive Cell Fusion: Consequences for Propagation in the Brain,”EMBO J.,1998, 17(14):3899-3909.
Cathomen et al., “Measles Viruses with Altered Envelope Protein Cytoplasmic Tails Gain Cell Fusion Competence,”J. Virol.,1998, 72(2):1224-1234.
Chambers et al., “Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in ascidmouse model of human malignant glioma,”Proc. Natl. Acad. Sci. USA,1995, 92:1411-1415.
Ch'ien et al., “Fatal Subacute Immunosuppressive Measles Encephalitis (SIME) in Children with Acute Lymphcytic Leukemia—Clinical, Electroencephalographic, and Computerized Tomographic Scan Features,”Clin. Electroencephalogr.,1983, 14(4):214-220.
Cohen et al., “Complete nucleotide sequence of an attenuated hepatitis A virus: Comparison with wild-type virus,”Proc. Natl. Acad. Sci. USA,1987, 84:2497-2501.
Crawford et al., “Thyroid volume measurement in thyrotoxic patients: comparison between ultrasonography and iodine- 124 positron emission tomography,”Eur. J. Nucl. Med.,1997, 24:1470-1478.
Dai et al., “Cloning and characterization of the thyroid iodide transporter,”Nature,1996, 379:458-460.
de Felipe et al., “Use
Fielding Adele
Grote Deanna
Peng Kah-Whye
Russell Stephen James
Campell Bruce R.
Lucas Zachariah
Mayo Foundation for Medical Education and Research
LandOfFree
Method for limiting the growth of cancer cells using an... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for limiting the growth of cancer cells using an..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for limiting the growth of cancer cells using an... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3643362